Aktis Oncology (NASDAQ:AKTS) Reaches New 1-Year Low – Should You Sell?

Aktis Oncology (NASDAQ:AKTS)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $18.80 and last traded at $18.90, with a volume of 181220 shares traded. The stock had previously closed at $19.75.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Aktis Oncology to a “hold” rating in a research note on Saturday.

Aktis Oncology Stock Down 5.0%

Insider Buying and Selling at Aktis Oncology

In related news, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider owned 10,260,064 shares of the company’s stock, valued at $184,681,152. This trade represents a 12.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Helen Susan Kim bought 835,000 shares of the business’s stock in a transaction on Monday, January 12th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the director directly owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. This trade represents a 17.26% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 6,117,776 shares of company stock valued at $110,119,968 over the last quarter.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.